Winton Group’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-24,993
| Closed | -$1.29M | – | 1074 |
|
|
2022
Q3 | $1.29M | Sell |
24,993
-3,044
| -11% | -$126K | 0.08% | 329 |
|
|
2022
Q2 | $695K | Buy |
28,037
+4,827
| +21% | +$106K | 0.04% | 606 |
|
|
2022
Q1 | $582K | Sell |
23,210
-11,821
| -34% | -$332K | 0.03% | 637 |
|
|
2021
Q4 | $1.27M | Buy |
35,031
+20,528
| +142% | +$721K | 0.08% | 378 |
|
|
2021
Q3 | $248K | Sell |
14,503
-20,990
| -59% | -$327K | 0.01% | 1171 |
|
|
2021
Q2 | $475K | Buy |
35,493
+19,589
| +123% | +$483K | 0.03% | 953 |
|
|
2021
Q1 | $815K | Sell |
15,904
-397
| -2% | -$23.9K | 0.05% | 584 |
|
|
2020
Q4 | $1.01M | Sell |
16,301
-51,420
| -76% | -$2.94M | 0.07% | 408 |
|
|
2020
Q3 | $3.71M | Buy |
67,721
+62,726
| +1,256% | +$3.38M | 0.12% | 237 |
|
|
2020
Q2 | $287K | Sell |
4,995
-13,320
| -73% | -$725K | 0.01% | 1292 |
|
|
2020
Q1 | $736K | Sell |
18,315
-68,633
| -79% | -$2.91M | 0.02% | 907 |
|
|
2019
Q4 | $3.44M | Buy |
86,948
+71,509
| +463% | +$1.26M | 0.05% | 599 |
|
|
2019
Q3 | $105K | Buy |
+15,439
| New | +$116K | ﹤0.01% | 1459 |
|
|
2019
Q2 | – | Sell |
-12,677
| Closed | -$176K | – | 1322 |
|
|
2019
Q1 | $176K | Buy |
+12,677
| New | +$145K | ﹤0.01% | 981 |
|
Other funds holding CCXI
Winton Group's CCXI Position: Q4 2022 in Review
Winton Group sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 24,993 shares — an estimated $1.29M sold.
Winton Group first reported a position in CCXI in Q1 2019 and held it in 14 quarters. The position peaked at $3.71M in Q3 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Winton Group reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Winton Group sold 24,993 ChemoCentryx, Inc. shares in Q4 2022, an estimated $1.29M.
- Winton Group first reported a position in ChemoCentryx, Inc. in Q1 2019 and held it in 14 quarters.
- Winton Group's ChemoCentryx, Inc. position peaked at $3.71M in Q3 2020.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Winton Group's 13F filing for Q4 2022, filed 14 Feb 2023.